Galapagos NV balance sheet GLPGF

Annual Quarterly

Cash and investments were $40.0 million.

USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the year before.

Line
FY 2025
Dec 31, 2025
FY 2024
Dec 31, 2024
FY 2023
Dec 31, 2023
FY 2022
Dec 31, 2022
FY 2021
Dec 31, 2021
FY 2019
Dec 31, 2019
FY 2018
Dec 31, 2018
FY 2017
Dec 31, 2017
Assets
Cash
40
-0.7%
40
+16.8%
34
-64.5%
97
-88.0%
808
657
+105.0%
320
+32.8%
241
Cash and investments
40
-0.7%
40
+16.8%
34
-64.5%
97
-88.0%
808
657
+105.0%
320
+32.8%
241
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. More on our methodology.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
LKFT (Nasdaq), GLPGF (OTC)
Incorporated in
Belgium
Headquarters
2800 Mechelen
SEC filer status
Large accelerated filer
SEC CIK
1421876
Former names
GALAPAGOS NV (until May 6, 2026)

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.